Pharmaron | Pharmaron API Commercial Synthesis Coventry (US)

The Pharmaron Coventry site, located in Rhode Island, USA, was acquired by Pharmaron in 2022, further strengthening the company’s technological capabilities and service offerings.

Coventry is an FDA-approved facility equipped with reactors ranging from 50 L to 8,000 L, enabling batch production from just a few grams to several hundred kilograms. The site supports the full development lifecycle—from clinical phases through to commercial manufacturing.

The facility is organized into a PR&D/pilot plant building and a commercial-scale production building, with a combined reactor capacity of 76,000 L.

Coventry stands out for its large-scale hydrogenation capabilities and is DEA-approved to manufacture controlled substances across Schedules I to V.

The site also plays a key role in Pharmaron’s successful hybrid China–US model: advanced intermediates are produced in China, shipped to Coventry, and converted into final APIs in the US. This model ensures a robust, flexible supply chain while maintaining cost-efficiency (COGs).